NLS Pharmaceutics AG [NLSP] is 35.14% higher this YTD. Is it still time to buy?



NLS Pharmaceutics AG [NASDAQ: NLSP] gained 26.05% or 0.31 points to close at $1.50 with a heavy trading volume of 169404257 shares. The company report on January 4, 2022 that NLS Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation.

Key patent now granted in major markets including the U.S., Europe, Canada & South Korea.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Patent claims cover use of the Company’s lead product candidate, Quilience® (mazindol ER) in both attention deficit hyperactivity disorder (ADHD) & narcolepsy.

It opened the trading session at $1.32, the shares rose to $2.40 and dropped to $1.26, the range by which the price of stock traded the whole day. The daily chart for NLSP points out that the company has recorded -51.30% loss over the past six months. However, it is still -36.36% lower than its most recent low trading price.

If we look at the average trading volume of 850.75K shares, NLSP reached to a volume of 169404257 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about NLS Pharmaceutics AG [NLSP]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NLSP shares is $10.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NLSP stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

The Average True Range (ATR) for NLS Pharmaceutics AG is set at 0.23 The Price to Book ratio for the last quarter was 3.95, with the Price to Cash per share for the same quarter was set at 0.57.

Trading performance analysis for NLSP stock

NLS Pharmaceutics AG [NLSP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 21.95. With this latest performance, NLSP shares gained by 11.94% in over the last four-week period, additionally sinking by -51.30% over the last 6 months .

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NLSP stock in for the last two-week period is set at 54.15, with the RSI for the last a single of trading hit 64.32, and the three-weeks RSI is set at 48.27 for NLS Pharmaceutics AG [NLSP]. The present Moving Average for the last 50 days of trading for this stock 1.7191, while it was recorded at 1.2160 for the last single week of trading, and 2.6838 for the last 200 days.

NLS Pharmaceutics AG [NLSP]: A deeper dive into fundamental analysis

NLS Pharmaceutics AG’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.90 and a Current Ratio set at 6.90.

>> 7 Top Picks for the Post-Pandemic Economy <<

An analysis of insider ownership at NLS Pharmaceutics AG [NLSP]

There are presently around $0 million, or 1.10% of NLSP stock, in the hands of institutional investors. The top three institutional holders of NLSP stocks are: UBS GROUP AG with ownership of 62,473, which is approximately 3145.351% of the company’s market cap and around 45.57% of the total institutional ownership; TWO SIGMA ADVISERS, LP, holding 27,300 shares of the stock with an approximate value of $32000.0 in NLSP stocks shares; and CITADEL ADVISORS LLC, currently with $24000.0 in NLSP stock with ownership of nearly 93.857% of the company’s market capitalization.

5 institutional holders increased their position in NLS Pharmaceutics AG [NASDAQ:NLSP] by around 111,450 shares. Additionally, 1 investors decreased positions by around 41,997 shares, while 0 investors held positions by with 18,724 shares. The mentioned changes placed institutional holdings at 134,723 shares, according to the latest SEC report filing. NLSP stock had 2 new institutional investments in for a total of 24,502 shares, while 1 institutional investors sold positions of 41,997 shares during the same period.